Decipher Biosciences, Dendreon Pharmaceuticals Ink Prostate Cancer Research Deal

Feb 15, 2019

NEW YORK (GenomeWeb) — Decipher Biosciences — formerly GenomeDx Biosciences — announced today that it has signed an agreement to help Dendreon Pharmaceuticals identify patients who are likely to respond to its prostate cancer therapy Provenge (sipuleucel-T).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Featured White Papers

The BD Veritor Plus System

Advancing Patient Care and Aiding Diagnosis at the Point of Care

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Immuno-Oncology: 3 Strategies for Applying Humanized Models

Mar

26

Featured Webinar

Advancing Agricultural Genomics with Low-Cost NGS Genotyping

This webinar will address the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

Mar

28

Featured Webinar

The Human Gene Mutation Database: Empowering a Generation of Geneticists for Precision Medicine

The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive collection of disease-causing, germline mutations. Since 1996, a team of experts has manually catalogued over a quarter of a million mutations for the database.

Apr

11

Featured Webinar

The 'Dark Matter' of Cancer Genomics: Revealing Undetected Structural Variants in Leukemia

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.

Menu